Education/Working Experience

1994-1999  Graduate,Changchun Inst of Applied Chemistry, Chinese Academy of Science

2000-2001  Postdoctor, Institute of Biological structure, CEA/CNRS, Grenoble, France

2001-2002 Research Associate, Clark University, Worcester, MA

2002-2003  Postdoctor, University of Massachusetts Medical School, Worcester, MA

2003-2005 Research Associate, Albert Einstein College of Medicine, Bronx, NY

2005-2007 Research Associate, Case Western Reserve University, Cleveland, OH

2010-2011  Advanced visiting scientist, University of Oxford, Oxford, UK

2007-  Professor, Dept. of Biotechnology, Dalian Medical University

Participation in the Academic Community

Member of Dalian Medical Association (Biochemistry)

Member of Dalian Medical Association (Biomedical Engineering)

Publication

(Publication authorized as corresponding or first authorrecently)

1. Biomedicine &Pharmacotherapy , 2016 , 84: 645-654

2. The Journal of Animal and Plant Sciences, 2016, 26(1): 233-241.

3. Oncotarget, Epub. Feb. 18, 2016;DOI: 10.18632/ oncotarget.7484.

4. Future Oncology.2016, 12(1): 31-42.

5. Scientific Reports. 2015, 5:18215.

6. Oncology Letters, 2015, 10: 1947-1952.

7. Biochimie, 2015, 116: 34-52.

8. Clin Chim Acta,2015，447: 72-78.

9. Biomedicine & Pharmacotherapy 2015, 71: 84-90.

10. Biomedicine & Pharmacotherapy, 2015, 70: 58-63.

11. Future Oncology, 2014, 10(16): 2687-2697.

12. The Journal of Animal and Plant Sciences, 2014, 24(3): 926-935.

13. Iranian Journal of Pharmaceutical Research, 2014, 13(3): 1019-1028.

14. Annexin A11 in disease. Clin Chim Acta,2014,431: 164-168.

15. Clin Chim Acta, 2014, 427:42-48.

16. The Journal of Animal & Plant Sciences, 2013, 23(5):1398-1406.

17. Future Oncology, 2013, 9(11): 1773-1793.

18. Clin Chim Acta, 2013, 423: 83-89.

19. The Anatomical Record,2013, 296: 807-814.

20. Clinical and Translational Oncology,2013, 15(3): 167-172.

21. Clinical and Translational Oncology, 2013,15(2):106-110.

22. ACTB in cancer. Clin Chim Acta, 2013, 417: 39-44.

23. Clinical and Translational Oncology,2012, 14(9): 634-640.

24. J. Photochem. Photobiol. B., 2012,114: 94-101.

25. Biomedicine & Pharmacotherapy,2012,66(4): 242-248.

26. Toxicon, 2012,60(3):302-311.

27. African Journal of Biotechnology, 2012, 11(44): 10242-10247.

28. Clinical and Translational Oncology. 2012, 14 (1):21-30.

29. The Protein Journal,2012,31(1):51-58.

30. The Anatomical Record, 2011, 294(2):273-282.

31. BMB reports, 2010, 43(8): 554-560.

32. Biochimie, 2010, 92(7):901-908.

33. Biochimie.2010, 92: 343-349.

34. 高等学校化学学报, 2009, 30(10): 1965-1971.

35. 高等学校化学学报,2009, 30(9):1773-1778.

36. 高等学校化学学报, 2009, 30(3): 517-524.

37. Proteomics, 2009,9(12):3285-3302.

38. Biochimie, 2009,91:558-567.

39. Rapid Communications in Mass Spectrometry, 2009, 23(8):1158-1166.

40. Journal of Biotechnology, 2008, 136S: S82.

41. Journal of Biotechnology, 2008, 136S: S187.

42. Journal of Biotechnology, 2008, 136S: S751 (SCI).

43. 高等学校化学学报, 2008, 29(11): 2194-2200

44. Toxicon, 2008, 52 (7): 760-768

45. Rapid Communications in Mass Spectrometry, 2008, 22(20): 3172-3178.

46. BBA, Protein and Proteomics, 2006, 1764: 1340-1348

47. BBRC, 2006, 348: 1279-1287

Molecular and Cellular Proteomics, 2006, 6(10): 808

Research Projects/Grants

1.2017.1-2020.12,Thestudy on the action mechanism of ceRNA in tumor lymphatic metastasis by regulating miR-330-3p and Ereg and its clinical significance in tumors, 530,000 RMB.

2.Natural Foundation of Liaoning Province (2014023047):ANXA11 regulates the tumorigenesis and drug-resistance of tumor cell with low lymphatic metastasis potential, 50,000 RMB.

3.NSFC(81171957): 2012.1-2015.12,The associations of Anax3, Anax5 and Anxa11 with lymphatic metastasis potential of tumor cells and tumor metastasis, as well as the identification of their co-regulated proteins in tumor cells, 550,000 RMB.

Admission Plan/Requirements

2 M.S. Graduate Candidates

2Ph.D.Graduate Candidates